explore -WSS

explore

author：hotspot 2025-09-27 12:57:26 - browse：16

Surrounded by tablets, an elder miniature figure walks with a cane next to a stethoscope — coverage from STAT — Adobe

Medicare Advantage is arguably the most controversial health care program right now — a sentiment that was bolstered Friday by striking new data about overpayments and an uncommon political jab during a routine meeting of policy wonks.

The Medicare Payment Advisory Commission, a group that advises Congress on Medicare policy, gathered to discuss its pending March report on the state of Medicare Advantage, the alternative to traditional Medicare that is run by health insurance companies. Medicare Advantage is expected to cost taxpayers $507 billion this year, according to the latest federal estimates.

The group, known as MedPAC, came to several familiar conclusions from the staff’s presentation and report: The federal government significantly overpays Medicare Advantage insurers because they attract healthier, lower-cost people into their plans and then excessively code those people’s health conditions — making Medicare Advantage a drain on taxpayers. MedPAC’s staffers also reiterated that Medicare Advantage’s quality rating system is “not a good basis for judging quality,” and therefore leads to further overpayments because insurers are paid bonuses based on this quality system.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： CDC recommends rationing of RSV shot due to shortages

entertainment

WSS

The stability of $0 premiums in Medicare Advantage

New oral drug delivery patch is modeled after octopus tentacles

What we owe ALS patients — and why one company fell short

Readout Newsletter: What happened with Sarepta's Duchenne data

Why Sanofi got shellacked over its spinoff

First Opinion Podcast: How to protect health care in times of war

hotspot

explore

focus

ChatGPT in medicine: STAT answers readers' burning questions

Setback for rare diseases as Taysha Gene Therapies pulls back

Medicare details structure of new drug price negotiation program

Nobel honors Karikó and Weissman's enduring partnership

Moonlake's readout produced a cash windfall. Risks remain

Will an HIV vaccine ever be a reality?

The cancer drug shortage isn’t new — and neither are the solutions

WHO recommends second malaria vaccine

Peter Hotez and the public health issue of online harassment

Traditional Chinese medicine benefits explored in new JAMA study

focus

Experts study whether long Covid risk adds up with each reinfection

Congress extends some pandemic preparedness programs

Maker of FluMist seeks to allow at

Biden's order seeks to regulate AI risk without stifling innovation

What we owe ALS patients — and why one company fell short

WHO may add ‘noma' to its list of neglected tropical diseases

explore

Wikipedia

entertainment

knowledge